Nicholas F. Dybdal-Hargreaves

Nicholas F. Dybdal-Hargreaves

Auto-generated profile, based on publicly available information

Nicholas F. Dybdal-Hargreaves

UT Health Science Center at San Antonio, San Antonio, TX

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Journal of Endodontics
Verified
Journal Article
Closed access
ETErnesto G. Trevino
Ernesto G. Trevino
APAmol N. Patwardhan
Amol N. Patwardhan
MHMichael A. Henry
Michael A. Henry
GPGriffin Perry
Griffin Perry
NDNicholas Dybdal-Hargreaves
Nicholas Dybdal-Hargreaves
ADAnibal Diogenes
Anibal Diogenes

7 April 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JCJordan M. Chinai
Jordan M. Chinai
ATAlexander B Taylor
Alexander B Taylor
LRLisa M. Ryno
Lisa M. Ryno
NHNicholas D. Hargreaves
Nicholas D. Hargreaves
CMChristopher A. Morris
Christopher A. Morris
AUAdam R. Urbach
Adam R. Urbach

31 May 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NDNicholas F. Dybdal-Hargreaves
Nicholas F. Dybdal-Hargreaves
ARApril L. Risinger
April L. Risinger
SMSusan Mooberry
Susan Mooberry
Eribulin mesylate (eribulin), an analogue of the marine natural product halichondrin B, is a microtubule-depolymerizing drug that has utility in the treatment of patients with breast cancer. Clinical trial results have demonstrated that eribulin treatment provides a survival advantage to patients with metastatic or locally advanced breast cancer previously treated with an anthracycline and a taxane. Furthermore, a pooled analysis of two pivotal phase III trials has demonstrated that eribulin also improves overall survival in several patient subgroups, including in women with HER2-negative disease and triple-negative breast cancer. This review covers the preclinical research that led to the clinical testing and approval of eribulin, as well as subsequent research that was prompted by distinct and unexpected effects of eribulin in the clinic. Initial studies with halichondrin B demonstrated unique effects on tubulin binding that resulted in distinct microtubule-dependent events and antitumor actions. Consistent with the actions of the natural product, eribulin has potent microtubule-depolymerizing activities and properties that distinguish it from other microtubule-targeting agents. Here, we review new results that further differentiate the effects of eribulin from other agents on peripheral nerves, angiogenesis, vascular remodeling, and epithelial-to-mesenchymal transition. Together, these data highlight the distinct properties of eribulin and begin to delineate the mechanisms behind the increased survival benefit provided by eribulin for patients. Clin Cancer Res; 21(11); 2445–52. ©2015 AACR.

1 July 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
XZXin Zhang
Xin Zhang
SRSudhir Raghavan
Sudhir Raghavan
MIMichael Ihnat
Michael Ihnat
JTJessica E. Thorpe
Jessica E. Thorpe
BDBryan C. Disch
Bryan C. Disch
AGAleem Gangjee
Aleem Gangjee

1 August 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
NDNicholas F. Dybdal-Hargreaves
Nicholas F. Dybdal-Hargreaves
NHNicholas Holder
Nicholas Holder
POPaige E. Ottoson
Paige E. Ottoson
MSMelanie D. Sweeney
Melanie D. Sweeney
TWTyisha Williams
Tyisha Williams

1 February 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AGAleem Gangjee
Aleem Gangjee
NZNilesh Zaware
Nilesh Zaware
RDRavi Kumar Vyas Devambatla
Ravi Kumar Vyas Devambatla
SRSudhir Raghavan
Sudhir Raghavan
CWCara D. Westbrook
Cara D. Westbrook
SMSusan Mooberry
Susan Mooberry